Skip to content
BeOne Medicines
-
BeOne Medicines collaborates with Revolution Medicines on RAS-targeted cancer treatments
The agreement covers joint clinical studies that will combine BeOne’s oncology pipeline with four clinical-stage RAS(ON) inhibitors developed by Revolution Medicines: daraxonrasib, zoldonrasib, elironrasib and RMC-5127.
-
BeOne Medicines invests US$300M in New Jersey to expand US onshoring footprint
The company plans to construct a new three-story, 145,000-square-foot facility for drug product manufacturing and packaging next to its existing operations.
-
BeOne Medicines secures US$20M option on Huahui Health’s trispecific cancer antibody HH160
If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.